These events follow the successful clinical application of small molecules, decoy receptors, and humanized Abs targeting IL‐1β or its signaling receptor, which became standard treatments against autoinflammatory syndromes (Kuijk et al, 2007; Calligaris et al, 2008; van der Hilst et al, 2016), and have also shown clinical benefits against conditions such as atherosclerosis (Ridker et al, 2017a), lung cancer (Ridker et al, 2017b), gout (Janssen et al, 2019), and RA (Ruscitti et al, 2019; Chauhan et al, 2020). The gene discussed is IL1B; the disease is atherosclerosis.